Allied Market Research
Loading...
Cart
0
PURCHASE OPTIONS

Start reading instantly ,This title and over 12000 thousand more,available with Avenue Library, T&C*

New
New Allied Market Research

Drug-Eluting Stents Market by Coating (Polymer-Based Coating and Polymer Free Coating), Application (Coronary Artery Disease and Peripheral Artery Disease), and End User (Hospitals, Ambulatory Surgical Centers, and Others): Global Opportunity Analysis and Industry Forecast, 2020–2027

A10604
Pages: 198
Mar 2021 | 131 Views
 
Author(s) : Trupti Wadekar, Sushant Terdale , Onkar Sumant
Tables: 120
Charts: 42
 

COVID-19

Pandemic disrupted the entire world and affected many industries.

Get detailed COVID-19 impact analysis on the Drug-eluting Stents Market

Request Now !

The global drug-eluting stents market was valued at $6,382 million in 2019, and is projected to reach $8,777 million by 2027, registering a CAGR of 8.7% from 2020 to 2027.

Drug-eluting stent (DES) is a peripheral or coronary stent placed into narrowed, diseased peripheral, or coronary arteries that slowly release a drug to block cell proliferation. Drug-eluting stents are coated with medication, which is released (eluted) to prevent growth of scar tissues in arterial walls. Eluted drug helps arteries to remain smooth and exposed, which ensures adequate blood flow and decrease in chances of restenosis. DES is regarded as the gold standard for treatment of coronary heart disease, as it offers various benefits such as enhanced vessel healing, minimally invasive nature, and reduced need for prolonged dual antiplatelet therapy. Patients implanted with DES are recommended to use certain medications or drug therapy. This therapy helps to decrease the risk of in-stent thrombosis, owing to a comparatively slower healing process.

Drug-Eluting-Stents-Market,-2020-2027

Get more information on this report : Request Sample Pages

Constant rise in geriatric population primarily drives growth of the drug-eluting stents market as geriatric population is at high risk of developing arterial disorders. In addition, unhealthy food habits, sedentary lifestyles, and lack of exercise increase the prevalence of atherosclerosis worldwide, which propels growth of the market. Moreover, rise in drug eluting stents product approvals and minimally-invasive techniques for DES placing augments growth of the drug eluting stent market. Furthermore, rise in prevalence of several cardiovascular diseases such as abnormal heart rhythms, heart attack, heart valve disease, congenital heart diseases, and heart failure function is expected to boost the growth of the market. However, stringent government regulations for product approval restricts growth of the market. Conversely, rise in potential in emerging economies is expected to create lucrative opportunities for the market growth during the forecast period.

COVID-19 pandemic has affected every industry worldwide. For instance, after COVID-19 was declared as a pandemic by the WHO, countries worldwide adopted nationwide lockdowns to observe social distancing as a measure to contain the spread. This led to disruption, limitation, challenges, and changes in each sector of every industry. Similarly, manufacturing and distributing companies drug-eluting stents have been affected by COVID-19 to a limited extent, owing to shutdowns in various COVID-19 affected countries and rise in number of healthcare workers falling ill in the wake of the COVID-19 pandemic, leading to short supply. 

Drug-eluting Stents Market Segmentation  

The global drug-eluting stents market is segmented on the basis of coating, application, end user, and region. On the basis of coating, the market is divided into polymer-based coating and polymer free coating. The polymer-based coating segment is further bifurcated into biodegradable and non-biodegradable. The polymer free coating segment is further divided into microporous surface, microstructured surface, slotted tubular surface, and nanoporous surface. By application, the market is categorized into coronary artery disease and peripheral artery disease. By end user, the market is bifurcated into hospitals, ambulatory surgical centers, and others. Region wise, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA. 

Drug-Eluting Stents Market
By Coating

Your browser does not support the canvas element.

Polymer free coating segment holds a dominant position in 2019 and would continue to maintain the lead over the forecast period.

Get more information on this report : Request Sample Pages

Segment review 

Presently, on the basis of coating, the polymer free coating segment is the major revenue contributor, and is projected to grow significantly during the forecast period. High adoption of DES is attributed to lower in-stent restenosis rates, quicker drug eluting rate, and higher drug loading capacity of nanoporous surfaces. Moreover, polymer free coating offers advantages such as inflammatory issues produced by polymers used in stents can be avoided by excluding polymer coating completely and releasing anti-proliferative drug directly from the stent surface.

By application, the coronary artery disease segment is the major shareholder in the global drug-eluting stents market, owing to rise in prevalence of coronary artery disease, surge in adoption of drug-eluting stents, and increase in product approvals of drug-eluting stents in coronary artery disease treatment.  

Drug-Eluting Stents Market
By End User

Your browser does not support the canvas element.

Hospitals segment is projected as one of the most lucrative segment.

Get more information on this report : Request Sample Pages

Snapshot of Asia-Pacific drug-eluting stents market  

Asia-Pacific presents lucrative opportunities for key players operating in the drug-eluting stents market, owing to increase in prevalence of coronary artery disease and peripheral artery disease, growth in patient awareness toward commercial availability of products, increase in geriatric population in emerging economies, development of the R&D sector, rise in healthcare reforms, and technological advancements in drug-eluting stents products. Moreover, surge in focus of leading manufacturers on expanding their geographical presence in emerging Asia-Pacific countries to capture high market share is expected to drive growth of the drug-eluting stents market in the region.

The key players profiled in this report include Abbott Laboratories, Alvimedica, B. Braun Holding GmbH & Co. KG, Biosensors International Group, Biotronik Inc., Boston Scientific Corporation, Cook Group (Cook Medical), Medtronic Plc, Stentys SA, and Terumo Corporation.

Drug-Eluting Stents Market
By Region

2027
North America 
Europe
Asia-pacific
Lamea

Asia-Pacific region would exhibit the highest CAGR of 10.0% during 2020-2027.

Get more information on this report : Request Sample Pages

Key Benefits For Stakeholders

  • The study provides an in-depth analysis of the drug-eluting stents market size along with the current trends and future estimations to elucidate the imminent investment pockets.
  • It offers drug-eluting stents market analysis from 2019 to 2027, which is expected to enable stakeholders to capitalize on prevailing opportunities in the market.
  • A comprehensive analysis of four regions is provided to determine the prevailing opportunities.
  • The profiles and growth strategies of the key players are thoroughly analyzed to understand the competitive outlook and global drug-eluting stents market growth.

Key Market Segments

By Coating

  • Polymer Based Coating
  • Biodegradable
  • Non-Biodegradable
  • Polymer Free Coating
  • Microporous Surface
  • Microstructured Surface
  • Slotted Tubular Surface
  • Nanoporous Surface

By Application

  • Coronary Artery Disease
  • Peripheral Artery Disease

By End User

  • Hospitals
  • Ambulatory Surgical Centers
  • Others

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China 
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • South Africa
    • Rest of LAMEA
 

CHAPTER 1:INTRODUCTION

1.1.Report description
1.2.Key Benefits for Stakeholders
1.3.Key market segments

1.3.1.List of key players profiled in the report

1.4.Research methodology

1.4.1.Secondary research
1.4.2.Primary research
1.4.3.Analyst tools and models

CHAPTER 2:EXECUTIVE SUMMARY

2.1.Key findings of the study
2.2.CXO perspective

CHAPTER 3:MARKET LANDSCAPE

3.1.Market definition and scope
3.2.Key findings

3.2.1.Top investment pockets
3.2.2.Top winning strategies

3.3.Porter’s five force analysis
3.4.Top player positioning, 2019
3.5.Market dynamics

3.5.1.Drivers

3.5.1.1.Rise in prevalence of cardiovascular disease
3.5.1.2.Surge  in demand for minimally invasive surgical procedures
3.5.1.3.Introduction of advanced drug eluting stents

3.5.2.Restraint

3.5.2.1.Stringent government regulations

3.5.3.Opportunities

3.5.3.1.Growth opportunities in emerging markets

3.5.4.Impact analysis

3.6.Covid-19 Impact analysis on drug-eluting stents market

CHAPTER 4:DRUG-ELUTING STENTS MARKET, BY COATING

4.1.Overview

4.1.1.Market size and forecast

4.2.Polymer based coating

4.2.1.Key market trends, growth factors, and opportunities
4.2.2.Market size and forecast, by region
4.2.3.Market analysis, by country
4.2.4.Market size and forecast, by type
4.2.5.Biodegradable

4.2.5.1.Market size and forecast

4.2.6.Non-biodegradable

4.2.6.1.Market size and forecast

4.3.Polymer free coating

4.3.1.Key market trends, growth factors, and opportunities
4.3.2.Market size and forecast
4.3.3.Market analysis, by country
4.3.4.Market size and forecast, by type
4.3.5.Microporous surface

4.3.5.1.Market size and forecast

4.3.6.Microstructured surface

4.3.6.1.Market size and forecast

4.3.7.Slotted tubular surface

4.3.7.1.Market size and forecast

4.3.8.Nanoporous surface

4.3.8.1.Market size and forecast

CHAPTER 5:DRUG-ELUTING STENTS MARKET, BY APPLICATION

5.1.Overview

5.1.1.Market size and forecast

5.2.Coronary artery disease

5.2.1.Market size and forecast, by region
5.2.2.Market analysis, by country

5.3.Peripheral artery disease

5.3.1.Market size and forecast, by region
5.3.2.Market analysis, by country

CHAPTER 6:DRUG-ELUTING STENTS MARKET, BY END USER

6.1.Overview

6.1.1.Market size and forecast

6.2.Hospitals

6.2.1.Market size and forecast, by region
6.2.2.Market analysis, by country

6.3.Ambulatory surgical centers

6.3.1.Market size and forecast, by region
6.3.2.Market analysis, by country

6.4.Others

6.4.1.Market size and forecast, by region
6.4.2.Market analysis, by country

CHAPTER 7:DRUG-ELUTING STENTS MARKET, BY REGION

7.1.Overview

7.1.1.Market size and forecast

7.2.North America

7.2.1.Key market trends, growth factors, and opportunities
7.2.2.Market size and forecast, by country

7.2.2.1.U.S.

7.2.2.1.1.U.S. drug-eluting stents market, by coating
7.2.2.1.2.U.S. drug-eluting stents market, by application
7.2.2.1.3.U.S. drug-eluting stents market, by end user

7.2.2.2.Canada

7.2.2.2.1.Canada drug-eluting stents market, by coating
7.2.2.2.2.Canada drug-eluting stents market, by application
7.2.2.2.3.Canada drug-eluting stents market, by end user

7.2.2.3.Mexico

7.2.2.3.1.Mexico drug-eluting stents market, by coating
7.2.2.3.2.Mexico drug-eluting stents market, by application
7.2.2.3.3.Mexico drug-eluting stents market, by end user

7.2.3.North America market size and forecast, by coating
7.2.4.North America market size and forecast, by application
7.2.5.North America market size and forecast, by end user

7.3.Europe

7.3.1.Key market trends, growth factors, and opportunities
7.3.2.Market size and forecast, by country

7.3.2.1.Germany

7.3.2.1.1.Germany drug-eluting stents market, by coating
7.3.2.1.2.Germany drug-eluting stents market, by application
7.3.2.1.3.Germany drug-eluting stents market, by end user

7.3.2.2.France

7.3.2.2.1.France drug-eluting stents market, by coating
7.3.2.2.2.France drug-eluting stents market, by application
7.3.2.2.3.France drug-eluting stents market, by end user

7.3.2.3.UK

7.3.2.3.1.UK drug-eluting stents market, by coating
7.3.2.3.2.UK drug-eluting stents market, by application
7.3.2.3.3.UK drug-eluting stents market, by end user

7.3.2.4.Italy

7.3.2.4.1.Italy drug-eluting stents market, by coating
7.3.2.4.2.Italy drug-eluting stents market, by application
7.3.2.4.3.Italy drug-eluting stents market, by end user

7.3.2.5.Spain

7.3.2.5.1.Spain drug-eluting stents market, by coating
7.3.2.5.2.Spain drug-eluting stents market, by application
7.3.2.5.3.Spain drug-eluting stents market, by end user

7.3.2.6.Rest of Europe

7.3.2.6.1.Rest of Europe drug-eluting stents market, by coating
7.3.2.6.2.Rest of Europe drug-eluting stents market, by application
7.3.2.6.3.Rest of Europe drug-eluting stents market, by end user

7.3.3.Europe market size and forecast, by coating
7.3.4.Europe market size and forecast, by application
7.3.5.Europe market size and forecast, by end user

7.4.Asia-Pacific

7.4.1.Key market trends, growth factors, and opportunities
7.4.2.Market size and forecast, by country

7.4.2.1.China

7.4.2.1.1.China drug-eluting stents market, by coating
7.4.2.1.2.China drug-eluting stents market, by application
7.4.2.1.3.China drug-eluting stents market, by end user

7.4.2.2.Japan

7.4.2.2.1.Japan drug-eluting stents market, by coating
7.4.2.2.2.Japan drug-eluting stents market, by application
7.4.2.2.3.Japan drug-eluting stents market, by end user

7.4.2.3.India

7.4.2.3.1.India drug-eluting stents market, by coating
7.4.2.3.2.India drug-eluting stents market, by application
7.4.2.3.3.India drug-eluting stents market, by end user

7.4.2.4.Australia

7.4.2.4.1.Australia drug-eluting stents market, by coating
7.4.2.4.2.Australia drug-eluting stents market, by application
7.4.2.4.3.Australia drug-eluting stents market, by end user

7.4.2.5.South Korea

7.4.2.5.1.South Korea drug-eluting stents market, by coating
7.4.2.5.2.South Korea drug-eluting stents market, by application
7.4.2.5.3.South Korea drug-eluting stents market, by end user

7.4.2.6.Rest of Asia-Pacific

7.4.2.6.1.Rest of Asia-Pacific drug-eluting stents market, by coating
7.4.2.6.2.Rest of Asia-Pacific drug-eluting stents market, by application
7.4.2.6.3.Rest of Asia-Pacific drug-eluting stents market, by end user

7.4.3.Asia-Pacific market size and forecast, by coating
7.4.4.Asia-Pacific market size and forecast, by application
7.4.5.Asia-Pacific market size and forecast, by end user

7.5.LAMEA

7.5.1.Key market trends, growth factors, and opportunities
7.5.2.Market size and forecast, by country

7.5.2.1.Brazil

7.5.2.1.1.Brazil drug-eluting stents market, by coating
7.5.2.1.2.Brazil drug-eluting stents market, by application
7.5.2.1.3.Brazil drug-eluting stents market, by end user

7.5.2.2.Saudi Arabia

7.5.2.2.1.Saudi Arabia drug-eluting stents market, by coating
7.5.2.2.2.Saudi Arabia drug-eluting stents market, by application
7.5.2.2.3.Saudi Arabia drug-eluting stents market, by end user

7.5.2.3.South Africa

7.5.2.3.1.South Africa drug-eluting stents market, by coating
7.5.2.3.2.South Africa drug-eluting stents market, by application
7.5.2.3.3.South Africa drug-eluting stents market, by end user

7.5.2.4.Rest of LAMEA

7.5.2.4.1.Rest of LAMEA drug-eluting stents market, by coating
7.5.2.4.2.Rest of LAMEA drug-eluting stents market, by application
7.5.2.4.3.Rest of LAMEA drug-eluting stents market, by end user

7.5.3.LAMEA market size and forecast, by coating
7.5.4.LAMEA market size and forecast, by application
7.5.5.LAMEA market size and forecast, by end user

CHAPTER 8:COMPANY PROFILES

8.1.ABBOTT LABORATORIES

8.1.1.Company overview
8.1.2.Company snapshot
8.1.3.Operating business segments
8.1.4.Product portfolio
8.1.5.Business performance
8.1.6.Key strategic moves and developments

8.2.ALVIMEDICA

8.2.1.Company overview
8.2.2.Company snapshot
8.2.3.Operating business segments
8.2.4.Product portfolio
8.2.5.Key strategic moves and developments

8.3.B. BRAUN HOLDING GMBH & CO. KG

8.3.1.Company overview
8.3.2.Company snapshot
8.3.3.Operating business segments
8.3.4.Product portfolio
8.3.5.Business performance

8.4.BIOSENSORS INTERNATIONAL GROUP, LTD

8.4.1.Company overview
8.4.2.Company snapshot
8.4.3.Operating business segments
8.4.4.Product portfolio
8.4.5.Key strategic moves and developments

8.5.BIOTRONIK, INC.

8.5.1.Company overview
8.5.2.Company snapshot
8.5.3.Operating business segments
8.5.4.Product portfolio
8.5.5.Key strategic moves and developments

8.6.BOSTON SCIENTIFIC CORPORATION

8.6.1.Company overview
8.6.2.Company snapshot
8.6.3.Operating business segments
8.6.4.Product portfolio
8.6.5.Business performance
8.6.6.Key strategic moves and developments

8.7.COOK GROUP (COOK MEDICAL)

8.7.1.Company overview
8.7.2.Company snapshot
8.7.3.Operating business segments
8.7.4.Product portfolio
8.7.5.Key strategic moves and developments

8.8.MEDTRONIC PLC.

8.8.1.Company overview
8.8.2.Company snapshot
8.8.3.Operating business segments
8.8.4.Product portfolio
8.8.5.Business performance
8.8.6.Key strategic moves and developments

8.9.STENTYS SA

8.9.1.Company overview
8.9.2.Company snapshot
8.9.3.Operating business segments
8.9.4.Product portfolio
8.9.5.Business performance

8.10.TERUMO CORPORATION

8.10.1.Company overview
8.10.2.Company snapshot
8.10.3.Operating business segments
8.10.4.Product portfolio
8.10.5.Business performance
8.10.6.Key strategic moves and developments

LIST OF TABLES

TABLE 01.DRUG-ELUTING STENTS MARKET, BY COATING, 2019–2027 ($MILLION)
TABLE 02.POLYMER BASED COATING DRUG-ELUTING STENTS MARKET, BY REGION, 2019–2027 ($MILLION)
TABLE 03.POLYMER BASED COATING DRUG-ELUTING STENTS MARKET, BY TYPE, 2019–2027, ($MILLION)
TABLE 04.POLYMER FREE COATING DRUG-ELUTING STENTS MARKET, BY REGION, 2019–2027 ($MILLION)
TABLE 05.POLYMER FREE COATING DRUG-ELUTING STENTS MARKET, BY TYPE, 2019–2027, ($MILLION)
TABLE 06.DRUG-ELUTING STENTS MARKET, BY APPLICATION, 2019–2027 ($MILLION)
TABLE 07.CORONARY ARTERY DISEASE DRUG-ELUTING STENTS MARKET, BY REGION, 2019–2027 ($MILLION)
TABLE 08.PERIPHERAL ARTERY DISEASE DRUG-ELUTING STENTS MARKET, BY REGION, 2019–2027 ($MILLION)
TABLE 09.DRUG-ELUTING STENTS MARKET, BY HOSPITALS, 2019–2027 ($MILLION)
TABLE 10.DRUG-ELUTING STENTS MARKET FOR HOSPITALS, BY REGION, 2019–2027 ($MILLION)
TABLE 11.DRUG-ELUTING STENTS MARKET FOR AMBULATORY SURGICAL CENTERS, BY REGION, 2019–2027 ($MILLION)
TABLE 12.DRUG-ELUTING STENTS MARKET FOR OTHERS, BY REGION, 2019–2027 ($MILLION)
TABLE 13.DRUG-ELUTING STENTS MARKET, BY REGION, 2019–2027 ($MILLION)
TABLE 14.NORTH AMERICA DRUG-ELUTING STENTS MARKET, BY COUNTRY, 2019–2027 ($MILLION)
TABLE 15.U.S. DRUG-ELUTING STENTS MARKET, BY COATING, 2019–2027
TABLE 16.U.S. DRUG-ELUTING STENTS MARKET, BY APPLICATION, 2019–2027
TABLE 17.U.S. DRUG-ELUTING STENTS MARKET, BY END USER, 2019–2027
TABLE 18.CANADA DRUG-ELUTING STENTS MARKET, BY COATING, 2019–2027
TABLE 19.CANADA DRUG-ELUTING STENTS MARKET, BY APPLICATION, 2019–2027
TABLE 20.CANADA DRUG-ELUTING STENTS MARKET, BY END USER, 2019–2027
TABLE 21.MEXICO DRUG-ELUTING STENTS MARKET, BY COATING, 2019–2027
TABLE 22.MEXICO DRUG-ELUTING STENTS MARKET, BY APPLICATION, 2019–2027
TABLE 23.MEXICO DRUG-ELUTING STENTS MARKET, BY END USER, 2019–2027
TABLE 24.NORTH AMERICA DRUG-ELUTING STENTS MARKET, BY COATING, 2019–2027
TABLE 25.NORTH AMERICA DRUG-ELUTING STENTS MARKET, BY APPLICATION, 2019–2027
TABLE 26.NORTH AMERICA DRUG-ELUTING STENTS MARKET, BY END USER, 2019–2027
TABLE 27.EUROPE DRUG-ELUTING STENTS MARKET, BY COUNTRY, 2019–2027 ($MILLION)
TABLE 28.GERMANY DRUG-ELUTING STENTS MARKET, BY COATING, 2019–2027
TABLE 29.GERMANY DRUG-ELUTING STENTS MARKET, BY APPLICATION, 2019–2027
TABLE 30.GERMANY DRUG-ELUTING STENTS MARKET, BY END USER, 2019–2027
TABLE 31.FRANCE DRUG-ELUTING STENTS MARKET, BY COATING, 2019–2027
TABLE 32.FRANCE DRUG-ELUTING STENTS MARKET, BY APPLICATION, 2019–2027
TABLE 33.FRANCE DRUG-ELUTING STENTS MARKET, BY END USER, 2019–2027
TABLE 34.UK DRUG-ELUTING STENTS MARKET, BY COATING, 2019–2027
TABLE 35.UK DRUG-ELUTING STENTS MARKET, BY APPLICATION, 2019–2027
TABLE 36.UK DRUG-ELUTING STENTS MARKET, BY END USER, 2019–2027
TABLE 37.ITALY DRUG-ELUTING STENTS MARKET, BY COATING, 2019–2027
TABLE 38.ITALY DRUG-ELUTING STENTS MARKET, BY APPLICATION, 2019–2027
TABLE 39.ITALY DRUG-ELUTING STENTS MARKET, BY END USER, 2019–2027
TABLE 40.SPAIN DRUG-ELUTING STENTS MARKET, BY COATING, 2019–2027
TABLE 41.SPAIN DRUG-ELUTING STENTS MARKET, BY APPLICATION, 2019–2027
TABLE 42.SPAIN DRUG-ELUTING STENTS MARKET, BY END USER, 2019–2027
TABLE 43.REST OF EUROPE DRUG-ELUTING STENTS MARKET, BY COATING, 2019–2027
TABLE 44.REST OF EUROPE DRUG-ELUTING STENTS MARKET, BY APPLICATION, 2019–2027
TABLE 45.REST OF EUROPE DRUG-ELUTING STENTS MARKET, BY END USER, 2019–2027
TABLE 46.EUROPE DRUG-ELUTING STENTS MARKET, BY COATING, 2019–2027
TABLE 47.EUROPE DRUG-ELUTING STENTS MARKET, BY APPLICATION, 2019–2027
TABLE 48.EUROPE DRUG-ELUTING STENTS MARKET, BY END USER, 2019–2027
TABLE 49.ASIA-PACIFIC DRUG-ELUTING STENTS MARKET, BY COUNTRY, 2019–2027 ($MILLION)
TABLE 50.CHINA DRUG-ELUTING STENTS MARKET, BY COATING, 2019–2027
TABLE 51.CHINA DRUG-ELUTING STENTS MARKET, BY APPLICATION, 2019–2027
TABLE 52.CHINA DRUG-ELUTING STENTS MARKET, BY END USER, 2019–2027
TABLE 53.JAPAN DRUG-ELUTING STENTS MARKET, BY COATING, 2019–2027
TABLE 54.JAPAN DRUG-ELUTING STENTS MARKET, BY APPLICATION, 2019–2027
TABLE 55.JAPAN DRUG-ELUTING STENTS MARKET, BY END USER, 2019–2027
TABLE 56.INDIA DRUG-ELUTING STENTS MARKET, BY COATING, 2019–2027
TABLE 57.INDIA DRUG-ELUTING STENTS MARKET, BY APPLICATION, 2019–2027
TABLE 58.INDIA DRUG-ELUTING STENTS MARKET, BY END USER, 2019–2027
TABLE 59.AUSTRALIA DRUG-ELUTING STENTS MARKET, BY COATING, 2019–2027
TABLE 60.AUSTRALIA DRUG-ELUTING STENTS MARKET, BY APPLICATION, 2019–2027
TABLE 61.AUSTRALIA DRUG-ELUTING STENTS MARKET, BY END USER, 2019–2027
TABLE 62.SOUTH KOREA DRUG-ELUTING STENTS MARKET, BY COATING, 2019–2027
TABLE 63.SOUTH KOREA DRUG-ELUTING STENTS MARKET, BY APPLICATION, 2019–2027
TABLE 64.SOUTH KOREA DRUG-ELUTING STENTS MARKET, BY END USER, 2019–2027
TABLE 65.REST OF ASIA-PACIFIC DRUG-ELUTING STENTS MARKET, BY COATING, 2019–2027
TABLE 66.REST OF ASIA-PACIFIC DRUG-ELUTING STENTS MARKET, BY APPLICATION, 2019–2027
TABLE 67.REST OF ASIA-PACIFIC DRUG-ELUTING STENTS MARKET, BY END USER, 2019–2027
TABLE 68.ASIA-PACIFIC DRUG-ELUTING STENTS MARKET, BY COATING, 2019–2027
TABLE 69.ASIA-PACIFIC DRUG-ELUTING STENTS MARKET, BY APPLICATION, 2019–2027
TABLE 70.ASIA-PACIFIC DRUG-ELUTING STENTS MARKET, BY END USER, 2019–2027
TABLE 71.LAMEA DRUG-ELUTING STENTS MARKET, BY COUNTRY, 2019–2027 ($MILLION)
TABLE 72.BRAZIL DRUG-ELUTING STENTS MARKET, BY COATING, 2019–2027
TABLE 73.BRAZIL DRUG-ELUTING STENTS MARKET, BY APPLICATION, 2019–2027
TABLE 74.BRAZIL DRUG-ELUTING STENTS MARKET, BY END USER, 2019–2027
TABLE 75.SAUDI ARABIA DRUG-ELUTING STENTS MARKET, BY COATING, 2019–2027
TABLE 76.SAUDI ARABIA DRUG-ELUTING STENTS MARKET, BY APPLICATION, 2019–2027
TABLE 77.SAUDI ARABIA DRUG-ELUTING STENTS MARKET, BY END USER, 2019–2027
TABLE 78.SOUTH AFRICA DRUG-ELUTING STENTS MARKET, BY COATING, 2019–2027
TABLE 79.SOUTH AFRICA DRUG-ELUTING STENTS MARKET, BY APPLICATION, 2019–2027
TABLE 80.SOUTH AFRICA DRUG-ELUTING STENTS MARKET, BY END USER, 2019–2027
TABLE 81.REST OF LAMEA DRUG-ELUTING STENTS MARKET, BY COATING, 2019–2027
TABLE 82.REST OF LAMEA DRUG-ELUTING STENTS MARKET, BY APPLICATION, 2019–2027
TABLE 83.REST OF LAMEA DRUG-ELUTING STENTS MARKET, BY END USER, 2019–2027
TABLE 84.LAMEA DRUG-ELUTING STENTS MARKET, BY COATING, 2019–2027
TABLE 85.LAMEA DRUG-ELUTING STENTS MARKET, BY APPLICATION, 2019–2027
TABLE 86.LAMEA DRUG-ELUTING STENTS MARKET, BY END USER, 2019–2027
TABLE 87.ABBOTT: COMPANY SNAPSHOT
TABLE 88.ABBOTT: OERATING SEGMENT
TABLE 89.ABBOTT: PRODUCT PORTFOLIO
TABLE 90.ABBOTT: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 91.ALVIMEDICA: COMPANY SNAPSHOT
TABLE 92.ALVIMEDICA: PRODUCT PORTFOLIO
TABLE 93.ALVIMEDICA: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 94.B BRAUN: COMPANY SNAPSHOT
TABLE 95.B BRAUN: OPERATING SEGMENTS
TABLE 96.B BRAUN: PRODUCT PORTFOLIO
TABLE 97.BIOSENSORS INTERNATIONAL: COMPANY SNAPSHOT
TABLE 98.BIOSENSORS INTERNATIONAL: PRODUCT PORTFOLIO
TABLE 99.BIOSENSORS INTERNATIONAL: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 100.BIOTRONIK: COMPANY SNAPSHOT
TABLE 101.BIOTRONIK: OPERATING SEGMENTS
TABLE 102.BIOTRONIK: PRODUCT PORTFOLIO
TABLE 103.BIOTRONIK: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 104.BOSTON: COMPANY SNAPSHOT
TABLE 105.BOSTON: OPERATING SEGMENTS
TABLE 106.BOSTON: PRODUCT PORTFOLIO
TABLE 107.COOK: COMPANY SNAPSHOT
TABLE 108.COOK: OPERATING SEGMENTS
TABLE 109.COOK: PRODUCT PORTFOLIO
TABLE 110.COOK: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 111.MEDTRONIC: COMPANY SNAPSHOT
TABLE 112.MEDTRONIC: OPERATING SEGMENTS
TABLE 113.MEDTRONIC: PRODUCT PORTFOLIO
TABLE 114.MEDTRONIC: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 115.STENTYS: COMPANY SNAPSHOT
TABLE 116.STENTYS: PRODUCT PORTFOLIO
TABLE 117.TERUMO: COMPANY SNAPSHOT
TABLE 118.TERUMO: OERATING SEGMENT
TABLE 119.TERUMO: PRODUCT PORTFOLIO
TABLE 120.ABBOTT: KEY STRATEGIC MOVES AND DEVELOPMENTS

LIST OF FIGURES

FIGURE 01.DRUG-ELUTING STENTS MARKET SEGMENTATION
FIGURE 02.TOP INVESTMENT POCKETS
FIGURE 03.TOP WINNING STRATEGIES, BY YEAR, 2018-2020
FIGURE 04.TOP WINNING STRATEGIES, BY DEVELOPMENT, 2018-2020
FIGURE 05.TOP WINNING STRATEGIES, BY COMPANY, 2018-2020
FIGURE 06.HIGH BARGAINING POWER OF SUPPLIERS
FIGURE 07.MODERATE BARGAINING POWER OF BUYERS
FIGURE 08.HIGH THREAT OF SUBSTITUTES
FIGURE 09.HIGH THREAT OF NEW ENTRANTS
FIGURE 10.MODERATE  INTENSITY OF RIVALRY
FIGURE 11.TOP PLAYER POSITIONING, 2019
FIGURE 12.IMPACT ANALYSIS
FIGURE 13.COMPARATIVE ANALYSIS OF POLYMER BASED COATING DRUG-ELUTING STENTS MARKET, BY COUNTRY, 2019 & 2027 ($MILLION)
FIGURE 14.BIODEGRADABLE POLYMER BASED COATING DRUG-ELUTING STENTS MARKET, 2019–2027, ($MILLION)
FIGURE 15.NON-BIODEGRADABLE POLYMER BASED COATING DRUG-ELUTING STENTS MARKET, 2019–2027, ($MILLION)
FIGURE 16.COMPARATIVE ANALYSIS OF POLYMER FREE COATING DRUG-ELUTING STENTS MARKET, BY COUNTRY, 2019 & 2027 ($MILLION)
FIGURE 17.MICROPOROUS SURFACE POLYMER FREE COATING DRUG-ELUTING STENTS MARKET, 2019–2027, ($MILLION)
FIGURE 18.MICROSTRUCTURED SURFACE POLYMER FREE COATING DRUG-ELUTING STENTS MARKET, 2019–2027, ($MILLION)
FIGURE 19.SLOTTED TUBULAR SURFACE POLYMER FREE COATING DRUG-ELUTING STENTS MARKET, 2019–2027, ($MILLION)
FIGURE 20.NANOPOROUS SURFACE POLYMER FREE COATING DRUG-ELUTING STENTS MARKET, 2019–2027, ($MILLION)
FIGURE 21.COMPARATIVE ANALYSIS OF CORONARY ARTERY DISEASE DRUG-ELUTING STENTS MARKET, BY COUNTRY, 2019 & 2027 ($MILLION)
FIGURE 22.COMPARATIVE ANALYSIS OF PERIPHERAL ARTERY DISEASE DRUG-ELUTING STENTS MARKET, 2019 & 2027 ($MILLION)
FIGURE 23.COMPARATIVE ANALYSIS OF DRUG-ELUTING STENTS MARKET FOR HOSPITALS, BY COUNTRY, 2019 & 2027 ($MILLION)
FIGURE 24.COMPARATIVE ANALYSIS OF DRUG-ELUTING STENTS MARKET FOR AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2019 & 2027 ($MILLION)
FIGURE 25.COMPARATIVE ANALYSIS OF DRUG-ELUTING STENTS MARKET FOR OTHERS, BY COUNTRY, 2019 & 2027 ($MILLION)
FIGURE 26.ABBOTT: NET SALES, 2017–2019 ($MILLION)
FIGURE 27.ABBOTT: REVENUE SHARE BY SEGMENT, 2019 (%)
FIGURE 28.ABBOTT: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 29.B BRAUN: NET SALES, 2017–2019 ($MILLION)
FIGURE 30.B BRAUN: REVENUE SHARE, BY SEGMENT, 2019 (%)
FIGURE 31.B BRAUN: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 32.BOSTON: NET SALES, 2017–2019 ($MILLION)
FIGURE 33.BOSTON: REVENUE SHARE, BY SEGMENT, 2019 (%)
FIGURE 34.BOSTON: REVENUE SHARE, BY REGION, 2019(%)
FIGURE 35.MEDTRONIC: NET SALES, 2018–2020 ($MILLION)
FIGURE 36.MEDTRONIC: REVENUE SHARE, BY SEGMENT, 2020 (%)
FIGURE 37.MEDTRONIC: REVENUE SHARE, BY REGION, 2020 (%)
FIGURE 38.STENTYS: NET SALES, 2017–2019 ($MILLION)
FIGURE 39.STENTYS: REVENUE SHARE BY REGION, 2019 (%)
FIGURE 40.TERUMO: NET SALES, 2017–2019 ($MILLION)
FIGURE 41.TERUMO: REVENUE SHARE BY SEGMENT, 2019 (%)
FIGURE 42.TERUMO: REVENUE SHARE, BY REGION, 2019 (%)

 
 

Drug-eluting stents are expandable tubes made up of metal inserted into arteries of patients suffering from atherosclerosis. These stents hold artery open to release a medication that prevents reoccurring of blockages and improves blood flow.

Rise in burden of cardiovascular diseases, rapid growth in aging population, surge in demand for minimally invasive procedures, increase in number of percutaneous coronary intervention (PCI) procedures, and technological advancements in drug-eluting stents are expected to drive growth of the drug-eluting stents market.

North America is expected to remain dominant during the forecast period, owing to increase in demand for drug-eluting stents in coronary artery disease and peripheral artery disease treatment, rise in geriatric population, and presence of major key players along with R&D centers. Moreover, Asia-Pacific and LAMEA are expected to offer lucrative opportunities to key players during the forecast period, owing to increase in patient awareness toward cardiovascular disease treatment.

 
PURCHASE OPTIONS

Start reading instantly ,This title and over 12000 thousand more,available with Avenue Library, T&C*

Reach out to us

Call us on
( U.S. - Canada toll free )
+1-800-792-5285,   
Int'l : +1-503-894-6022
( Europe )
+ 44-845-528-1300
Drop us an email at
help@alliedmarketresearch.com

FREQUENTLY ASKED QUESTIONS?
Our Report Looks Like This
 

A. The total market value of Drug-Eluting Stents market is $6,381.76 million in 2019.

A. The forcast period for Drug-Eluting Stents market is 2020 to 2027

A. The market value of Drug-Eluting Stents market in 2020 is $4,893.80 million.

A. The base year is 2019 in Drug-Eluting Stents market

A. Top companies such as Boston Scientific Corporation, Abbott Laboratories, Medtronic Plc, Biotronik Inc., Terumo Corporation, Cook Group (Cook Medical), and B. Braun Holding GmbH & Co. KG held a high market position in 2019. These key players held a high market postion owing to the strong geographical foothold in different regions.

A. Polymer free coating segment is the most influencing segment owing to lower in-stent restenosis rates, quicker drug eluting rate, and higher drug loading capacity of nanoporous surfaces propel the market growth. Moreover, polymer free coating offers advantages such as inflammatory issues produced by polymers used in stents can be avoided by excluding polymer coating completely and releasing anti-proliferative drug directly from the stent surface.

A. Rise in prevalence of cardiovascular diseases such as congenital heart disease, abnormal heart rhythms, heart valve disease, heart attack, and heart failure is expected to drive growth of the market. In addition, technological advancements in drug eluting stents design and stent delivery systems is another major factor that boosts the market growth. Moreover, rise in number of product approvals and favorable reimbursement policies, coupled with high incidence rate of artery diseases also fuel growth of the drug-eluting stents market

A. Asia-Pacific has the highest growth rate in the market which is growing due to the contribution of the following emerging countries such as China with a CAGR of 11.7%. This is due to increase in number of initiatives and enhanced investments from governments for the overall development of drug-eluting stents, and surge in prevalence of peripheral artery disease. Moreover, favorable reimbursement policies associated with cardiovascular disease treatment, high demand for drug delivery devices, and increase in public awareness towards the usage and benefits of these devices are the key reasons for the significant growth of the market

A. Drug-eluting stents (DES) are small tube like, semi-rigid device that aid in improving blood flow through arteries to heart by minimizing blockages.

A. Drug-Eluting Stents products used for treatment of coronary artery disease and peripheral artery disease.

Allied Market Research Allied Market Research Allied Market Research Allied Market Research Allied Market Research Allied Market Research Allied Market Research Allied Market Research Allied Market Research Allied Market Research Allied Market Research Allied Market Research Allied Market Research Allied Market Research Allied Market Research Allied Market Research Allied Market Research Allied Market Research Allied Market Research

RELATED TAGS

 

HAVE QUESTIONS?
SPEAK WITH ANALYST

 

DID YOU MISS ANYTHING?
DO YOU HAVE SPECIFIC REQUIREMENTS?

 

Download Sample

OR

Purchase Full Report of
Drug-Eluting Stents Market

  • Online Only
  • $3,712
  • Online cloud access only
  • Restricted print, copy, paste & download
  • Read only
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Data Pack
  • $4,125
  • Restricted to one authorized user
  • One print only
  • Available in
    Excel
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Single User
  • $6,168
  • Restricted to one authorized user
  • One print only
  • Available in Excel & PDF
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Five Users
  • $6,929
  • Limited to five authorized users
  • Print upto five copies
  • Available in Excel & PDF
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Enterprise
    License/PDF

  • $9,663
  • Unlimited
    within
    company/enterprise
  • Available in Excel & PDF
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Library Membership
  • $ 699/mo
  • Published Content
    E-access
  • Company Profiles
    E-access
  • Newly Added Content Access
  • 10 PDF
    Downloads
  • 5 Excel Data
    Pack Downloads
  • 250 Company Profiles PDF Downloads
  • Start reading instantly.
    This title and over 12,000+ are available on the Avenue Library. T&C*.

    Buy Now

*Taxes/Fees, if applicable will be added during checkout. All prices in USD

 

Why Allied Market Research?

 

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers

 
 

Featured Reports

 

Featured Readings

 

Get fresh content delivered

Get insights on topics that are crucial for your business. Stay abreast of your interest areas.

 
Get Industry Data Alerts
 

Why Allied Market Research?

 

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers